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Radiosurgery for the control of Glomus 
Jugulare Tumours 
M. E. Bari,A.A. Kemeny,D.M.C. Forster,M.W.R.Radatz  ( Department of Neurosurgery, Aga 
Khan University Hospital*, Karachi and Royal Hallamshire Hospital, Sheffield, UK. ) 
 
Introduction  
Glomus jugulare tumours though rare, are the most common tumours of the middle ear1 
and jugulotympanic paragangliomas are the second most common tumours of the 
temporal bone. The true incidence of this vascular tumour is unknown, but is estimated 
around one per million.1-3 
 
Glomus tumour was first described by Valentin but its definitive description is credited to 
Stacey Guild of John Hopkins who coined the term "Glomus Jugulare" in 1941.4 Glomus 
jugulare tumours arise from the paraganglion cells, which are closely associated with the 
vasculature and cranial nerves derived from the branchial arches (branchiomeric 
paraganglia). The paraganglia takes origin from the neural crest cells and belongs to the 
diffuse neuroendocrine system. All these cells can demonstrate neuropeptide content or 
secretion. Tumours arising from these cells are histologically similar to tumours arising 
in other chemoreceptors. Although every paraganglioma may potentially secrete 
catecholamines, clinically functioning paragangliomas are only 1-3% as a four to fivefold 
elevation of serum norepinephrine is necessary to produce detectable symptoms.5,6 
Paraganglia of the temporal bones are ovoid bodies measuring .1mm to 1.5mm in 
diameter.6 There are usually three bodies in each ear. They accompany Jacobson's nerve 
(tympanic branch of glossopharyngeal nerve) or Arnold's nerve (auricular branch of 
vagus nerve). 50% of the paraganglia are located in the jugular fossa, 10% in the mucosa 
of the promontory and approximately 20% are found in inferior tympanic calculus. 
Microscopy demonstrates clusters of the epitheliod (chief) cells and sustentacular cells 
enmeshed in a web of small blood vessels. 
 
Glomus jugulare are slow growing, locally invasive tumours, showing female 
preponderance and average age of presentation is between 50-60 years.7-10 Although 
there is no clear racial predilection, the glomus tumour seems to be more common in 
whites. Ten percent of the tumours are multicentric in origin in the non-familial cases. 
However this frequency for multicentricity is exaggerated in the familial glomus tumours 
25-50%. Glomus jugulare tumours are generally benign but 1-3% metastasise. The 
common sites for metastasis in order of decreasing frequency are lung, adjacent lymph 
nodes, liver, spine, ribs and spleen.6,11-13 
 
The interval from the first symptom to diagnosis is usually between 3-6 years. Symptoms 
are caused by the invasion of adjacent lower cranial nerves, mass effect, and high blood 
flow through the lesion (pulsatile tinnitus) or because of the neuroendocrine effects. The 
treatment of these tumours is controversial and consists of surgery, radiotherapy and 
embolization. Each has its proponents claiming one is better than the other. 
 
Methods  
Since 1985 in the national centre for stereotactic radiosurgery in Sheffield we have 
treated 14 cases of glomus jugulare tumour with the Leksell gamma knife. All except 
one, are being followed up at the local referring hospitals. Eight of these patients have 
been followed up for more than four years. Three out of these eight patients had a 
minimum follow-up of more than seven years. Four patients had follow-up between 5-6 
years, one patient for 4.4 years. Our knowledge about these patients is based on the 
clinical assessment of the referring neurosurgeons in their follow-up clinics. All patients 
apart from one were contacted on telephone to obtain an update on their condition. 
Repeat scans were done at yearly intervals at the referring hospital. Each patient had a 
minimum of 3 and a maximum of 5 MRIscans in the follow-up period. Two patients had 
check angiography and one had digital subtraction angiography. These scans were sent to 
our department to be compared with the treatment scans and measured objectively. 
Eligibility Criteria Tumours with maximum diameter less than 40mm in any 
dimension. No sign of raised intracranial pressure or mass effect. No 
neuroendocrine function (non functioning tumours only). The parameters studied 
included: radiological follow up and improvement, tumour size and volume 
changes, symptomatic improvement and development  
Results  
 
Patient Follow up  
 
The minimum radiological follow-up was 39 months, maximum 80 months, mean 44 
months. The minimum clinical follow-up was 52 months and maximum was 97 months, 
mean 74 months.  
 
Patient Demography and Symptoms  
 
There were 3 males and five female patients. All of them were white (Caucasians). The 
age of the patients ranged between 32-64 years. The symptom duration before the 
radiosurgery was 1-8 years. Clinical symptoms are shown in Table 1. 
 
Two patients had previous surgery; one had radiotherapy along with surgery. One patient 
had had unsuccessful embolization prior to radiosurgery. Four patients had stereotactic 
radiosurgery as primary treatment. 
 
Tumour size, volume, localization and control  
 
In our study one patient’s tumour was localised with a combination of CT scan and 
angiography with a combination of MRI and CT. Two patients had the combination of 
MRI scan and angiography and three patients’ tumours were localised with MRI scan 
alone. 
 The target volume of the tumours ranged between 800 cm to 6300cm3, mean 4025 cm3. 
Volume of the actual lesions ranged between 970 -10200 cm3. Target volume is the 
volume, which received the prescribed volume of radiation at the time of radiosurgery. 
The tumour volumes were measured on the MRI scans at the time of radiosurgery with 
the computer to give an accurate reading. The tumours were measured in three directions 
i.e. height, length, width and the maximum diameter in each direction was recorded. The 
maximum diameter of the tumour in any plane was between 15-38 mm. According to 
Fisch classification five patients were class C and three patients were Class D1 tumours. 
None of the eight tumours in this study increased in size during the follow-up period 
(Figure 1). Radiological improvement was seen in 5/8 (63%) patients. Reductions in the 
size of the tumours were slight to moderate.  
 
Dose of radiotherapy  
 
The maximum dose to the periphery of the tumour ranged between 16-25 Gray with 50% 
isodose curve. The first patient we treated in our centre received 20 Gray after him next 
five received 25 Gray and two other patients received 16 and 17 Gray respectively. In one 
patient (IB) the lesion volume was 7800 cm3 while the target volume was only 4300 
cm.3 This discrepancy is due to the fact that target volume was measured on an 
angiogram as our neuroradiologist felt more confidant to do the planning on angiogram 
rather than CT where tumour was poorly localised. The other patient (ED) received a sub 
optimal dose, as tumour coverage was partial. The tumour was extending into the neck 
and it was not possible to encompass whole of the tumour due technical limitations. 
Symptomatic improvement was experienced in 6/8 (75%) patients, consisting of 




Two patients showed neurological deficit after radiosurgery. One patient (No.3) 
presented to us with progressive facial weakness at the time of radiosurgery. His facial 
weakness continued to progress during the follow-up period, despite radiological control 
of the tumour. This patient had three operations for his glomus jugulare tumour 20 years 
ago and had also received 6000 rads of conventional fractionated radiotherapy after the 
surgery to the residual. It seems probable that his facial weakness is at least in part a late 
complication of the initial conventional radiation therapy (Figure 2). 
One patient (No. 2) showed a grade 2 (House-Brackmann) facial weakness two and half 
years after radiosurgery but at her last follow-up her facial nerve function was normal. 
All eight patients are stable after radiosurgery and have not required any further 
therapeutic intervention for their irradiated tumours, although one patient who had 
multicentric tumours was operated for her glomus vagale tumour on the opposite side. 





Subjectively only three patient had useful hearing at the time of radiosurgery. The 
hearing remained stable in two patients and in one there was a subjective improvement. 
 
Discussion  
Glomus jugulare tumours present a formidable management problem because of their 
location and persistent invasive growth albeit usually slow and indolent. Surgical 
treatment of these tumours often causes considerable morbidity because of the extensive 
nature of skull-based procedures. With technical advancement in the surgical field, high 
speed drills and better microscopes, the focus of glomus jugulare tumour surgery has 
drifted away from the issue of resectability, virtually all of the glomus jugulare tumours 
are resectable (86-94%)10,13-18. Anand et al were able to claim complete resection of 
the tumour in 100% of cases.19 Nowadays the emphasis is towards the functional 
outcome. 
 
Most of these patients are able to compensate for their progressive chronic loss of 
function in the lower cranial nerves but it is the acute onset of lower cranial nerve 
dysfunction after an operation which gives rise to more trouble. In the published surgical 
series the risk of post operative lower cranial nerve dysfunction is around 50-
83%.10,13,15-19 The nerves most commonly effected are glossopharyngeal, vagus, 
accessory and hypoglossal (31-83%) with the need to repair the paralysed vocal cords in 
19% and gastrostomy in 4%. Facial nerve weakness was seen in 16-23% of the cases, 
while the abducent nerve was affected in 6% of the cases. Hearing impairment or 
deafness was seen in 4-26%.8,10,14,20-22 After the operation a substantial number of the 
patients are unable to maintain the same kind of life style, as they were able to enjoy prior 
to surgery. Other surgical complication includes wound infections, meningitis and CSF 
leaks. Another consideration is the long hospital stay after the operation. In one series of 
20 cases the post operative duration of hospital stay was between (8-67days)23, as most 
of these (19-42%) needed adjuvant surgery such as vocal cords injection, tarrsorrhaphy, 
cricopharyngeal myotomy, thyroplasty, gastrostomy and facial nerve anastomosis. Even 
after macroscopically complete resection these patients have to be followed-up for long 
periods as recurrence can occur after 20 years.6,14,22,24 Surgery is not without the risk 
of mortality. The reported mortality is in the order of 0-6%.1,10-12,13,15,18,19 
 
Glomus Jugulare tumour is not particularly radiosensitive and the presence of vital 
tumour cells can be seen long after radiotherapy.11,22 The changes after the radiotherapy 
consist of necrosis, oedema, hemosiderin deposition, fibrosis, and vascular changes 
consisting of myeloid degeneration of the vessel wall, intimal proliferation and 
thrombosis.23 Many people believe that the effect of radiotherapy is through the 
devitalisation caused by the obliteration of the vessels. In the past conventional 
fractionated radiotherapy was used most for recurrent tumours, medically unfit patients or 
inoperable cases. The requisite dose is considered to be 45-50 Gray given over 4-5 
weeks. The tumour control rates achieved in published series are between 69-
100%.18,24-29 The goal of radiotherapy treatment is tumour control and treatment is 
considered a success if there is no tumour progression in the follow-up. Radiotherapy 
showed subjective improvements in the clinical symptoms of the patients in around 70% 
of the cases22. However radiotherapy is not without complications, minor complications 
7%, and severe complications like bone and brain necrosis around 2%.22,26 Then there is 
a small risk of secondary malignancy.11  
 
Embolization of the feeding vessels is usually used as preoperative intervention to reduce 
the blood flow through the tumour. The ascending pharyngeal artery is the main vessel to 
these tumours but the tumour can receive blood supply from many other vessels namely 
the stylomastoid artery, middle meningeal branches of external carotid, carotico-
tympanic and meningeal branches of internal carotid or from the vertebral artery. Thus 
the complete obliteration of all the vessels is unlikely. As a preoperative intervention it 
was seen that it could decrease the amount of blood loss during the surgery by nearly 
1500cc. In a published series the average blood loss in embolized patients was around 
1122cc and in non-embolized patient it was around 2769cc. The average time for surgery 
was also consistently less in embolized patients. However contrary to the popular belief 
embolization didn't help in improved preservation of cranial nerves.22,30,31 
Embolization itself carries a significant risk of morbidity (10%)30 the most significant 
complication associated with embolization are stroke and death. other neurological deficit 
can occur including cranial nerve palsies. Hitherto embolization as a sole treatment 
option has to be considered a palliative measure since revascularization of the embolized 
vessels following endovascular occlusion occurs in 30% of the cases.18,30,32 Recently 
intratumoral embolization has been tried successfully; George et al32 injected a mixture 
of N-butylcyanoacrylate, lipiodol and tungsten in a 72 year old man with minor 
swallowing difficulties, sixteen months later the patient is in good condition without any 
evidence of tumour progression. 
 
Radiosurgery has proven beneficial for arteriovenous malformations so it was natural to 
try it for other lesions. To a greater extent than radiotherapy this patient friendly, precise 
single session narrow beam radiation therapy spares the normal brain tissue and effects 
are targeted to the tumour so the lesion gets a more effective dose. Radiosurgery has no 
reported mortality or acute morbidity. In the four published series of radiosurgery used 
for this purpose in English literature, no tumour has increased in size. Thus, hitherto, until 
now there is 100% tumour control without any mortality or acute morbidity. The largest 
series, the European multicentre experience, which includes six patients from our centre 
showed improvement in the neurological deficit in 19 patients out of the 52 patients 
followed over a long period of time. Permanent neurological complications were only 
seen in two patients. In one patient hearing and function of facial nerve deteriorated. The 
second patient also experienced progression in facial weakness. 
 
Our early results are comparable with the other Centres, as tumour control has been 
achieved without significant complications. In our experience radiosurgery has proven to 
be a cost effective procedure as the patient is only hospitalised for one or two nights, 
unlike radiotherapy and surgery. As no acute morbidity is seen, the patients normal 
lifestyle is not affected, so there is no economic loss because of inability to work.  
Conclusion  
Radiosurgery has proven to be a safe treatment for glomus jugulare tumour, however five 
year follow-up is not sufficient as glomus jugulare tumours are slow growing and 
recurrence after surgery has occurred even after 20 years of apparently "complete" 
cure.6,14,24 More time is necessary to establish the long-term effectiveness of 
stereotactic radiosurgery for the treatment of glomus jugulare tumour. 
 
At first surgery seems to be the only treatment which appears to offer a cure to the patient 
as usually it is possible to excise the tumour, but cure at what expense? Radiosurgery has 
proven to be an effective treatment and can control the growth of tumour without 
significant complication. We believe it should be used not only in the patients who are 
medically unfit or with recurrent tumours, but also should be considered as a primary 
treatment in suitable cases.  
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